Humana (HUM) Stock Forecast & Price Target

$258.07

+6.63 (+2.64%)

(As of 10/11/2024 ET)

Humana - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 25 Analyst Ratings

Sell
1

Hold
18

Buy
6

Based on 25 Wall Street analysts who have issued ratings for Humana in the last 12 months, the stock has a consensus rating of "Hold." Out of the 25 analysts, 1 has given a sell rating, 18 have given a hold rating, and 6 have given a buy rating for HUM.

Consensus Price Target

$315.33
22.19% Upside

According to the 25 analysts' twelve-month price targets for Humana, the average price target is $315.33. The highest price target for HUM is $550.00, while the lowest price target for HUM is $247.00. The average price target represents a forecasted upside of 22.19% from the current price of $258.07.

Get the Latest News and Ratings for HUM and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Humana and its competitors.

HUM Analyst Ratings Over Time

Type	Current Forecast 10/13/23 to 10/12/24	1 Month Ago 9/13/23 to 9/12/24	3 Months Ago 7/15/23 to 7/14/24	1 Year Ago 10/13/22 to 10/13/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	6 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	13 Buy rating(s)
Hold	18 Hold rating(s)	12 Hold rating(s)	13 Hold rating(s)	4 Hold rating(s)
Sell	1 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$315.33	$398.70	$409.55	$593.10
Forecasted Upside	22.19% Upside	22.87% Upside	7.15% Upside	17.22% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Next opportunity for crypto millions (Ad)

As we enter crypto's golden quarter (October-December), this coin is primed for takeoff. The best part? Most investors haven't caught on yet. This is your rare chance to be ahead of the curve.

Click here to uncover the crypto that could redefine wealth in Q4.

HUM Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

HUM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Humana Stock vs. The Competition

Type	Humana	Medical Companies	S&P 500
Consensus Rating Score	2.20	2.79	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	22.19% Upside	10,374.29% Upside	6.83% Upside
News Sentiment Rating	Neutral News See Recent HUM News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
10/11/2024	Truist Financial 2 of 5 stars		Lower Target	Hold ➝ Hold	$400.00 ➝ $260.00	+6.12%
10/11/2024	KeyCorp 3 of 5 stars	M. Gillmor Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Sector Weight
10/10/2024	Barclays 3 of 5 stars		Lower Target	Equal Weight ➝ Equal Weight	$364.00 ➝ $250.00	-0.38%
10/9/2024	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fidel Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$250.00 ➝ $250.00	+2.35%
10/8/2024	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$400.00 ➝ $265.00	+9.09%
10/8/2024	Sanford C. Bernstein Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Wilkes Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$308.00	+30.36%
Get the Latest News and Ratings for HUM and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Humana and its competitors with MarketBeat's FREE daily newsletter.
10/7/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Langston Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Hold	$402.00 ➝ $261.00	+10.13%
10/7/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold	$519.00 ➝ $253.00	+5.40%
10/4/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$380.00 ➝ $250.00	+3.31%
10/3/2024	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Hold ➝ Hold	$349.00 ➝ $250.00	+3.70%
10/3/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Tassan Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral	$392.00 ➝ $274.00	+11.93%
10/3/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$400.00 ➝ $280.00	+13.59%
10/2/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	W. Mayo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
10/2/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Neutral ➝ Underperform	$376.00 ➝ $247.00	+0.44%
10/2/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform	$400.00 ➝ $250.00	+6.05%
10/1/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Neutral ➝ Neutral	$395.00 ➝ $395.00	+30.14%
8/21/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$332.00 ➝ $396.00	+10.69%
6/24/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Equal Weight	$374.00	+5.21%
5/30/2024	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Ha Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
5/30/2024	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Neutral	$374.00	+8.31%
4/8/2024	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$413.00 ➝ $350.00	+11.78%
4/3/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$450.00 ➝ $385.00	+24.47%
3/22/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Market Perform
3/13/2024	Argus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Buy ➝ Hold
1/26/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$550.00 ➝ $400.00	+10.46%
4/27/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$640.00 ➝ $600.00	+18.70%
2/6/2023	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$647.00 ➝ $581.00	+21.91%
2/6/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$635.00 ➝ $575.00	+20.65%
11/7/2022	Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$547.00 ➝ $647.00	+17.20%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 06:10 AM ET.

Should I Buy Humana Stock? HUM Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Friday, October 11, 2024. Please send any questions or comments about these Humana pros and cons to contact@marketbeat.com.

Humana
Bull Case

Here are some ways that investors could benefit from investing in Humana Inc.:

Humana's stock price has shown resilience, currently trading at a lower price, potentially presenting a buying opportunity for investors.
Humana has consistently delivered strong quarterly earnings results, surpassing analyst expectations, indicating a healthy financial performance.
With a dividend yield of 1.11%, Humana offers investors a steady income stream through regular dividend payments.
Analysts have given Humana a consensus rating of "Hold," suggesting stability and potential for long-term growth.
Humana's focus on providing medical and specialty insurance products in the U.S. positions it well in a stable and growing market.

Humana
Bear Case

Investors should be bearish about investing in Humana Inc. for these reasons:

Humana's stock price has experienced a significant decline, potentially indicating underlying issues or market concerns.
Recent rating adjustments by analysts, including downgrades and lowered price targets, may signal uncertainties surrounding the company's future performance.
Humana's PEG ratio of 2.44 suggests a relatively high valuation compared to its expected earnings growth, potentially limiting upside potential for investors.
The company's debt-to-equity ratio of 0.70 may raise concerns about its financial leverage and ability to manage debt obligations effectively.
Stephens' downgrade from an "overweight" rating to an "equal weight" rating with a reduced target price reflects a shift in sentiment towards Humana's stock.

HUM Forecast - Frequently Asked Questions

: According to the research reports of 25 Wall Street equities research analysts, the average twelve-month stock price forecast for Humana is $315.33, with a high forecast of $550.00 and a low forecast of $247.00.
: 25 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Humana in the last year. There is currently 1 sell rating, 18 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" HUM shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HUM, but not buy additional shares or sell existing shares.
: According to analysts, Humana's stock has a predicted upside of 22.19% based on their 12-month stock forecasts.
: Over the previous 90 days, Humana's stock had 7 downgrades and 1 upgrade by analysts.
: Humana has been rated by research analysts at Bank of America, Barclays, Cantor Fitzgerald, Deutsche Bank Aktiengesellschaft, Jefferies Financial Group, JPMorgan Chase & Co., KeyCorp, Leerink Partners, Leerink Partnrs, Oppenheimer, Piper Sandler, Royal Bank of Canada, Sanford C. Bernstein, Stephens, TD Cowen, Truist Financial, and UBS Group in the past 90 days.
: Analysts like Humana less than other "medical" companies. The consensus rating for Humana is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how HUM compares to other companies.

Stock Forecasts and Research Tools

Related Companies:

Today's Ratings:

Top Rated Stocks:

More Ratings Tools:

Next opportunity for crypto millions (Ad)

As we enter crypto's golden quarter (October-December), this coin is primed for takeoff. The best part? Most investors haven't caught on yet. This is your rare chance to be ahead of the curve.

Click here to uncover the crypto that could redefine wealth in Q4.

This page (NYSE:HUM) was last updated on 10/12/2024 by MarketBeat.com Staff

From Our Partners